Table 2. Pairwise comparisons of ORR in different chemotherapy regimens.
| ORR | P-value | ||
|---|---|---|---|
| Oxaliplatin vs cisplatin doublets | IT | 44.4% vs 28.5% | 1.0000 |
| DT | 40.7% vs 34.0% | 0.1692 | |
| Anthracyclines vs platinum–fluoropyrimidine doublets | IT | 60.0% vs 37.5% | 0.0048 |
| DT | 40.8% vs 36.7% | 1.0000 | |
| Docetaxel vs platinum–fluoropyrimidine doublets | IT | 61.5% vs 37.5% | 0.0124 |
| DT | 51.0% vs 36.7% | 0.3796 | |
| Docetaxel vs anthracyclines | IT | 61.8% vs 60.0% | 0.8597 |
| DT | 51.0% vs 40.8% | 0.9791 |
Abbreviations: DT=diffuse type; IT=intestinal type; ORR=overall response rate. Data set: subjects with response-evaluable (at 3 months) and initially measurable disease (n=730). Test used: χ2; P-values were corrected using the Holm–Bonferroni method.